Cyberonics Depression Study Yields Benefit In Treatment-Resistant Patients
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will present data from its D-04 depression trial in July to determine if venous nerve stimulation (VNS) was responsible for a marked improvement in depression symptoms compared to its D-02 study
You may also be interested in...
Cyberonics Shares Up 14% In June, Stimulated By Pending D-04 Trial Results
The promise of a concrete regulatory timeline for Cyberonics' NeuroCybernetic Prosthesis vagus nerve stimulation therapy for depression, coupled with a $50 mil. investment by Boston Scientific, drove the firm's stock price up 13.8% in June
Cyberonics Shares Up 14% In June, Stimulated By Pending D-04 Trial Results
The promise of a concrete regulatory timeline for Cyberonics' NeuroCybernetic Prosthesis vagus nerve stimulation therapy for depression, coupled with a $50 mil. investment by Boston Scientific, drove the firm's stock price up 13.8% in June
Pediatric VNS Study Supports Cyberonics’ Focus On Epilepsy Growth Strategy
Cyberonics may expand use of its vagus nerve stimulation (VNS) therapy device to children with drug-resistant epilepsy aged 12 and younger, following positive results from a small study conducted by the Children's Hospital at The Cleveland Clinic